Particle manufacturing specialist Liquidia Technologies has named Benjamin Yerxa, most recently at Clearside Biomedical, as its new Chief Scientific Officer. Yerxa will oversee R&D, “including a focus on scientific collaborations,” for the company. Liquidia’s PRINT nanofabrication technology can produce particles of specified sizes and shapes for inhalation powders and other delivery methods.
Liquidia CEO Neal Fowler said, “We are very pleased to welcome Ben to the Liquidia team and strongly believe his entrepreneurial spirit and scientific expertise and vision will play an important role in helping us realize the full potential of our PRINT technology. Ben’s scientific and corporate accomplishments exemplify Liquidia’s passion to bring novel products to market that have the potential to transform patients’ lives.”
Read the Liquidia press release.
